tadalafil has been researched along with dipyridamole in 5 studies
Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (dipyridamole) | Trials (dipyridamole) | Recent Studies (post-2010) (dipyridamole) |
---|---|---|---|---|---|
1,742 | 392 | 1,089 | 7,826 | 881 | 632 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hughes, RA; Manallack, DT; Thompson, PE | 1 |
Beghyn, TB; Bourin, A; Charton, J; Cos, P; Deprez, B; Laconde, G; Leroux, F; Maes, L | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Aronsen, L; Lysaa, R; Orvoll, E; Ravna, AW; Sager, G | 1 |
2 review(s) available for tadalafil and dipyridamole
Article | Year |
---|---|
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Cyclic AMP; Cyclic GMP; Drug Design; Humans; Models, Molecular; Molecular Structure; Phosphodiesterase Inhibitors; Quantitative Structure-Activity Relationship; Xanthines | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for tadalafil and dipyridamole
Article | Year |
---|---|
Drug to genome to drug: discovery of new antiplasmodial compounds.
Topics: Amino Acid Sequence; Antimalarials; Carbolines; Catalytic Domain; Cyclic AMP; Cyclic GMP; Diketopiperazines; Drug Design; Drug Discovery; Genome, Human; Genome, Protozoan; Humans; Hydrolysis; Models, Molecular; Molecular Sequence Data; Parasitic Sensitivity Tests; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Plasmodium falciparum; Stereoisomerism; Structure-Activity Relationship; Tadalafil | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Modulation of high affinity ATP-dependent cyclic nucleotide transporters by specific and non-specific cyclic nucleotide phosphodiesterase inhibitors.
Topics: ATP-Binding Cassette Transporters; Caffeine; Carbolines; Cyclic AMP; Cyclic GMP; Dipyridamole; Humans; Imidazoles; Kinetics; Multidrug Resistance-Associated Proteins; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purinones; Sulfones; Tadalafil; Theophylline; Triazines; Vardenafil Dihydrochloride | 2014 |